Sartorius Stedim Biotech Releases Universal Registration Document 2025
Aubagne, France – 16 February 2026 – Sartorius Stedim Biotech, a global partner of the biopharmaceutical sector, announced the publication of its Universal Registration Document 2025, which includes the company’s Annual Financial Report. The document is accessible online at https://www.sartorius.com/urd2025 .
Financial Calendar
| Event | Date |
|---|---|
| Financial calendar release | 24 March 2026 |
| Annual Shareholders’ Meeting | 23 April 2026 |
| Publication of first‑quarter results (January–March 2026) | 23 July 2026 |
| Publication of half‑year results (January–June 2026) | 23 July 2026 |
| Publication of nine‑month results (January–September 2026) | 22 October 2026 |
Company Profile
Sartorius Stedim Biotech is headquartered in Aubagne, France, and operates manufacturing and R&D sites as well as sales entities across Europe, North America, and Asia. The company specialises in laboratory technologies and equipment for the biopharmaceutical industry, supporting the production of biopharmaceuticals such as cell and gene therapies. It expands its product portfolio through acquisitions of complementary technologies.
2025 Performance
Preliminary figures for 2025 indicate sales revenue of approximately €3 billion. The organisation employs more than 10,200 individuals who serve customers worldwide.
Contact Information
Verena Sattel, External Communications +49 551 308 9261verena.sattel@sartorius.com
The Universal Registration Document 2025 is now available for investors and stakeholders through the company’s website.
